ICOTINIB for Lung adenocarcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 8 adverse event reports in the FDA FAERS database where ICOTINIB was used for Lung adenocarcinoma.
Most Reported Side Effects for ICOTINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Rash | 14 | 34.2% | 1 | 1 |
| Hypertension | 12 | 29.3% | 0 | 0 |
| Diarrhoea | 10 | 24.4% | 0 | 0 |
| Malignant neoplasm progression | 10 | 24.4% | 2 | 2 |
| Fatigue | 9 | 22.0% | 1 | 0 |
| Bone marrow failure | 7 | 17.1% | 0 | 1 |
| Proteinuria | 7 | 17.1% | 0 | 0 |
| Vomiting | 7 | 17.1% | 2 | 0 |
| Disease progression | 6 | 14.6% | 0 | 0 |
| Haemorrhage | 6 | 14.6% | 0 | 0 |
| Nausea | 6 | 14.6% | 2 | 0 |
| Anaemia | 5 | 12.2% | 0 | 0 |
| Leukopenia | 5 | 12.2% | 0 | 0 |
| Liver injury | 5 | 12.2% | 0 | 1 |
Other Indications for ICOTINIB
Other Drugs Used for Lung adenocarcinoma
PEMETREXED (4,280)
PEMBROLIZUMAB (3,954)
CARBOPLATIN (3,888)
BEVACIZUMAB (1,522)
PACLITAXEL (1,216)
NIVOLUMAB (1,162)
ATEZOLIZUMAB (1,032)
CISPLATIN (1,003)
DOCETAXEL (977)
OSIMERTINIB (936)